



CAVA HEALTHCARE INC.
(FORMERLY ALTERNATIVE EXTRACTS INC.)
PRESS RELEASE

CAVA HEALTHCARE INC. ANNOUNCES A NAME CHANGE AND CHANGE IN THE COMPANY'S OFFICERS AND DIRECTORS

Vancouver, British Columbia, June 27, 2019 – Çava Healthcare Inc. ("CAVA" or the "Company"), is pleased to announce a name change, and change in Officers and Directors of the Company.

Effective June 19, 2019 the Company has changed its name to Çava Healthcare Inc.

Effective June 21, 2019 the Company has accepted the resignation of Mr. Mike Withrow as Chief Executive Officer ("CEO"), Mr. Withrow remains as a Director of the Company.

Effective June 22, 2019 the Company has accepted the resignation of Mr. Guy Dancosse as Director of the Company. The Company would like to thank Mr. Dancosse for his efforts and wish him continued success in his future business endeavours.

Effective June 22, 2019 the Company has accepted the resignation of Dr. Adrian Wade as Chief Science Officer of the Company. Mr. Wade will remain Chief Financial Officer and Director of the Company.

Effective June 21, 2019 the Company has appointed of Mr. Samuel Mercer as CEO and a Director of the Company.

Mr. Samuel Mercer has over 18 years of pharmaceutical development experience, previously managing outsourcing of global clinical trials, academic alliances, and pharma licensing. He obtained his Bachelor of Science Degree in Biochemistry from the University of Victoria. He previously directly negotiated over USD 600 million in agreements for both Roche (F. Hoffmann-La Roche Ltd.) and Novartis International AG in Basel, Switzerland. Prior to this, he managed proposals, contracts, and business development at several global contract research organizations in the United Kingdom and North America. More recently, he has worked as an executive, and advisor to several biotechnology startups. His focus is on technology development, executing clinical trials, regulatory processes, financial modelling, startup-company strategy and funding and the negotiation of complex business partnering agreements.

Effective June 26, 2019 the Company has appointed Dr. Wilfred Jefferies as Chief Science Officer, Chairman of the Board and as a Director of the Company.

Dr. Wilfred Jefferies is a Professor at the University of British Columbia, where he had been conducting research and mentoring students and post-doctoral researchers for over 25 years. He obtained his Bachelor of Science in Biochemistry from the University of Victoria and then obtained his Doctor of Philosophy in Molecular Immunology from the Sir William Dunn School of Pathology, at the University of Oxford. He subsequently conducted post-doctoral research at the Institut Suisse de Recherches Expérimentales sur le Cancer in Lausanne, Switzerland and later trained at the Ludwig Institute for Cancer Research (LICR), in the Karolinska Institute in Stockholm, Sweden. Professor Jefferies is currently a member of the Michael Smith Laboratories at University of British Columbia, and the Vancouver Prostate Centre (VPC) at Vancouver General Hospital (VGH) where he is the Head of Immune Oncology. He is an author of over 100 peer reviewed manuscripts including pioneering studies

describing pathology of the blood brain barrier (BBB) in Alzheimer's Disease and the interrelation between immune system subversion and cancer progression. He is an inventor and patent holder of technologies that form the basis of several biotechnology companies currently active in Canada and the USA.

For further information, contact the Company at info@cavahealthcare.com or (604) 803-8439.

On behalf of the Board,

Adrian Wade, PhD
Director

ÇAVA HEALTHCARE INC.

ÇAVA IS FOCUSED ON ENHANCING OPTIMAL HEALTH BY PREDICTING, PREVENTING AND ALLEVIATING DISEASE

Chronic and acute inflammation and poor immune function are at the core of developing disease. ÇAVA is addressing this unmet healthcare challenge through isolation and characterization of novel compounds from medicinal plant extraction, creation of novel biomarkers for disease, and application of cutting-edge technologies to reverse inflammation and restore immune function to achieve optimal health.

FORWARD LOOKING INFORMATION

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX-V) accepts responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws. This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on www.sedar.com.